LABP 66
Alternative Names: LABP-66; NX-66Latest Information Update: 29 May 2024
At a glance
- Originator Landos Biopharma
- Class Anti-inflammatories; Antidementias; Small molecules
- Mechanism of Action NLR protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Encephalomyelitis; Multiple sclerosis
Most Recent Events
- 23 May 2024 Landos Biopharma has been acquired by AbbVie
- 21 Mar 2024 Landos Biopharma has patents pending for LABP 66 in Australia, Brazil, Canada, Chile, China, Europe, Hong Kong, India, Israel, Japan, Mexico, New Zealand, and South Korea
- 09 Jun 2022 Landos Biopharma plans a phase I trial in Multiple sclerosis, in 2022